Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV
Objectives: To investigate immunogenicity of SARS-CoV-2 vaccine third booster dose (3BD; fifth dose) with bivalent vaccine original/BA4/5 vaccine in people living with HIV (PLWH). Methods: This is an observational cohort study to evaluate the outcomes of SARS-CoV-2 vaccination (HIV-VAC study). We an...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S120197122300632X |
| _version_ | 1797752967526350848 |
|---|---|
| author | Alessandra Vergori Giulia Matusali Alessandro Cozzi Lepri Eleonora Cimini Marisa Fusto Francesca Colavita Roberta Gagliardini Stefania Notari Valentina Mazzotta Davide Mariotti Stefania Cicalini Enrico Girardi Francesco Vaia Fabrizio Maggi Andrea Antinori |
| author_facet | Alessandra Vergori Giulia Matusali Alessandro Cozzi Lepri Eleonora Cimini Marisa Fusto Francesca Colavita Roberta Gagliardini Stefania Notari Valentina Mazzotta Davide Mariotti Stefania Cicalini Enrico Girardi Francesco Vaia Fabrizio Maggi Andrea Antinori |
| author_sort | Alessandra Vergori |
| collection | DOAJ |
| description | Objectives: To investigate immunogenicity of SARS-CoV-2 vaccine third booster dose (3BD; fifth dose) with bivalent vaccine original/BA4/5 vaccine in people living with HIV (PLWH). Methods: This is an observational cohort study to evaluate the outcomes of SARS-CoV-2 vaccination (HIV-VAC study). We analyzed microneutralization assay and interferon-γ production in 48 PLWH on antiretroviral therapy with clusters of differentiation (CD4) count <200 cell/mm3 and/or previous AIDS according to immunization status: vaccinated PLWH who had a previous SARS-CoV-2 infection (hybrid immunization, HI) vs those only vaccinated (non-hybrid immunization, nHI) and current CD4 count. Results: After 15 days from its administration (T1), the 3BD bivalent messenger RNA vaccine elicited a statistically significant increase of neutralizing antibodies (nAbs) geometric mean titers from T0 to T1 against W-D614G (fold increase 4.8; P <0.0001), BA.5 (8.6 P <0.0001), BQ.1.1 (6.4, P <0.0001) and XBB.1 (6.5, P <0.0001). When compared to BA.5, nAbs geometric mean titers against BQ.1.1 and XBB.1 decreased by 3.5 and 4.1-fold, respectively. After controlling for age, years from AIDS diagnosis, CD4 count at administration and CD4 count nadir, the fold change reduction in nAbs response to other variants of concerns as compared to BA.1, was larger in participants with HI vs those nHI: 0.59 lower (95% confidence interval 0.36-0.97, P = 0.04) for BQ.1.1 and 0.67 lower (95% confidence interval: 0.47-0.96, P = 0.03) for XBB.1. In contrast, the analysis carried little evidence for an association between current CD4 count and response to the fifth dose of bivalent vaccine. Furthermore, cell-mediated immunity remained stable. Conclusion: Our data support the current recommendation of offering bivalent mRNA vaccine booster doses to PLWH with low CD4 count or previous AIDS at first vaccination, especially in those who never previously acquired SARS-CoV-2 and regardless of current CD4 count. |
| first_indexed | 2024-03-12T17:12:08Z |
| format | Article |
| id | doaj.art-351a2d8456fe4ceab581805880010ba5 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-03-12T17:12:08Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-351a2d8456fe4ceab581805880010ba52023-08-06T04:36:44ZengElsevierInternational Journal of Infectious Diseases1201-97122023-09-01134195199Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIVAlessandra Vergori0Giulia Matusali1Alessandro Cozzi Lepri2Eleonora Cimini3Marisa Fusto4Francesca Colavita5Roberta Gagliardini6Stefania Notari7Valentina Mazzotta8Davide Mariotti9Stefania Cicalini10Enrico Girardi11Francesco Vaia12Fabrizio Maggi13Andrea Antinori14National Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, HIV/AIDS Unit, Rome, Italy; Corresponding author: Tel: +39 06 55170546.National Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, Laboratory of Virology, Rome, ItalyInstitute for Global Health, University College of London, Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), London, UKNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, Immunology Unit, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, HIV/AIDS Unit, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, Laboratory of Virology, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, HIV/AIDS Unit, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, Immunology Unit, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, HIV/AIDS Unit, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, Laboratory of Virology, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, HIV/AIDS Unit, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospitaller and Care Institutions, Scientific Direction, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, General Direction, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, Laboratory of Virology, Rome, ItalyNational Institute for Infectious Diseases Lazzaro Spallanzani, Scientific Hospital and Care Institutions, HIV/AIDS Unit, Rome, ItalyObjectives: To investigate immunogenicity of SARS-CoV-2 vaccine third booster dose (3BD; fifth dose) with bivalent vaccine original/BA4/5 vaccine in people living with HIV (PLWH). Methods: This is an observational cohort study to evaluate the outcomes of SARS-CoV-2 vaccination (HIV-VAC study). We analyzed microneutralization assay and interferon-γ production in 48 PLWH on antiretroviral therapy with clusters of differentiation (CD4) count <200 cell/mm3 and/or previous AIDS according to immunization status: vaccinated PLWH who had a previous SARS-CoV-2 infection (hybrid immunization, HI) vs those only vaccinated (non-hybrid immunization, nHI) and current CD4 count. Results: After 15 days from its administration (T1), the 3BD bivalent messenger RNA vaccine elicited a statistically significant increase of neutralizing antibodies (nAbs) geometric mean titers from T0 to T1 against W-D614G (fold increase 4.8; P <0.0001), BA.5 (8.6 P <0.0001), BQ.1.1 (6.4, P <0.0001) and XBB.1 (6.5, P <0.0001). When compared to BA.5, nAbs geometric mean titers against BQ.1.1 and XBB.1 decreased by 3.5 and 4.1-fold, respectively. After controlling for age, years from AIDS diagnosis, CD4 count at administration and CD4 count nadir, the fold change reduction in nAbs response to other variants of concerns as compared to BA.1, was larger in participants with HI vs those nHI: 0.59 lower (95% confidence interval 0.36-0.97, P = 0.04) for BQ.1.1 and 0.67 lower (95% confidence interval: 0.47-0.96, P = 0.03) for XBB.1. In contrast, the analysis carried little evidence for an association between current CD4 count and response to the fifth dose of bivalent vaccine. Furthermore, cell-mediated immunity remained stable. Conclusion: Our data support the current recommendation of offering bivalent mRNA vaccine booster doses to PLWH with low CD4 count or previous AIDS at first vaccination, especially in those who never previously acquired SARS-CoV-2 and regardless of current CD4 count.http://www.sciencedirect.com/science/article/pii/S120197122300632XAIDSmRNA bivalent vaccineOmicron sub-variantsNeutralizing antibodiesT-specific cell immunity |
| spellingShingle | Alessandra Vergori Giulia Matusali Alessandro Cozzi Lepri Eleonora Cimini Marisa Fusto Francesca Colavita Roberta Gagliardini Stefania Notari Valentina Mazzotta Davide Mariotti Stefania Cicalini Enrico Girardi Francesco Vaia Fabrizio Maggi Andrea Antinori Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV International Journal of Infectious Diseases AIDS mRNA bivalent vaccine Omicron sub-variants Neutralizing antibodies T-specific cell immunity |
| title | Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV |
| title_full | Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV |
| title_fullStr | Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV |
| title_full_unstemmed | Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV |
| title_short | Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV |
| title_sort | neutralizing activity and t cell response after bivalent fifth dose of messenger rna vaccine in people living with hiv |
| topic | AIDS mRNA bivalent vaccine Omicron sub-variants Neutralizing antibodies T-specific cell immunity |
| url | http://www.sciencedirect.com/science/article/pii/S120197122300632X |
| work_keys_str_mv | AT alessandravergori neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT giuliamatusali neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT alessandrocozzilepri neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT eleonoracimini neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT marisafusto neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT francescacolavita neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT robertagagliardini neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT stefanianotari neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT valentinamazzotta neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT davidemariotti neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT stefaniacicalini neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT enricogirardi neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT francescovaia neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT fabriziomaggi neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv AT andreaantinori neutralizingactivityandtcellresponseafterbivalentfifthdoseofmessengerrnavaccineinpeoplelivingwithhiv |